IMACEN

Imacen is a biotechnology company specializing in the development of next-generation molecular imaging agents and radiopharmaceuticals. The company focuses on creating high-affinity ligands for targets such as prostate-specific membrane antigen (PSMA) and fibroblast activation protein (FAP) to improve the diagnosis and treatment of various cancers. By leveraging advanced radiochemistry and imaging technologies, Imacen aims to provide more precise tools for oncology, enabling better patient stratification and monitoring of therapeutic response. Their pipeline includes several promising candidates currently in the pre-clinical stage, designed to address unmet needs in solid tumor management.